Nan Fung Trinity
AVTX icon

Nan Fung Trinity’s Avalo Therapeutics AVTX Stock Holding History

Nan Fung Trinity’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.9M Hold
189,000
– – 0.28% 53
2026
Q2 		$3.49M Hold
189,000
– – 0.34% 52
2026
Q1 		$2.82M Hold
189,000
– – 0.31% 56
2025
Q4 		$3.43M Buy
+189,000
New +$3.19M 0.27% 68

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Nan Fung Trinity's AVTX Position: Q3 2026 in Review

Nan Fung Trinity held its Avalo Therapeutics (AVTX) position steady in Q3 2026 at 189,000 shares worth $2.9M. The position accounts for 0.28% of the portfolio, ranked #53.

Nan Fung Trinity first reported a position in AVTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $3.49M in Q2 2026. 47 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Nan Fung Trinity held 189,000 shares of Avalo Therapeutics worth $2.9M as of Q3 2026.
  • Nan Fung Trinity left its Avalo Therapeutics share count unchanged in Q3 2026.
  • Avalo Therapeutics made up 0.28% of Nan Fung Trinity's portfolio in Q3 2026, its #53 holding.
  • Nan Fung Trinity first reported a position in Avalo Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Nan Fung Trinity's Avalo Therapeutics position peaked at $3.49M in Q2 2026.
  • 47 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Nan Fung Trinity's 13F filing for Q3 2026, filed 6 Nov 2026.